Cargando…
Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease
BACKGROUND: As an anti-TNF agent that targets inflammatory process directly, Pentoxifylline has been investigated for treatment of NASH in individual studies and pilot trials for years. We summarized the available information and generating hypotheses for future research. DATA SOURCES: Google, Cochr...
Autores principales: | Li, Wenjun, Zheng, Liu, Sheng, Chunjun, Cheng, Xiaoyun, Qing, Liu, Qu, Shen |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088890/ https://www.ncbi.nlm.nih.gov/pubmed/21477300 http://dx.doi.org/10.1186/1476-511X-10-49 |
Ejemplares similares
-
Pharmacological management of non-alcoholic fatty liver disease: Atorvastatin versus pentoxifylline
por: Cioboată, Ramona, et al.
Publicado: (2017) -
Pentoxifylline ameliorates non-alcoholic fatty liver disease in hyperglycaemic and dyslipidaemic mice by upregulating fatty acid β-oxidation
por: Ye, Jia-Hung, et al.
Publicado: (2016) -
The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD)
por: Liu, Qing, et al.
Publicado: (2010) -
Pentoxifylline Plus Prednisolone versus Pentoxifylline Only for Severe Alcoholic Hepatitis: A Randomized Controlled Clinical Trial
por: De, BK, et al.
Publicado: (2014) -
Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)